Literature DB >> 15149314

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

Bieke F Schrijvers1, Allan Flyvbjerg, An S De Vriese.   

Abstract

Vascular endothelial growth factor (VEGF) is an endothelial-specific growth factor that promotes endothelial cell proliferation, differentiation and survival, mediates endothelium-dependent vasodilatation, induces microvascular hyperpermeability and participates in interstitial matrix remodeling. In the kidney, VEGF expression is most prominent in glomerular podocytes and in tubular epithelial cells, while VEGF receptors are mainly found on preglomerular, glomerular, and peritubular endothelial cells. The role of VEGF in normal renal physiology is essentially unknown. The absence of prominent effects of VEGF blockade in normal experimental animals suggests a limited function during homeostasis, although a role in the formation and maintenance of glomerular capillary endothelial fenestrations has been suggested. VEGF and its receptors are up-regulated in experimental animals and humans with type 1 and type 2 diabetes. Inhibition of VEGF has beneficial effects on diabetes-induced functional and structural alterations, suggesting a deleterious role for VEGF in the pathophysiology of diabetic nephropathy. VEGF is required for glomerular and tubular hypertrophy and proliferation in response to nephron reduction, and loss of VEGF is associated with the development of glomerulosclerosis and tubulointerstitial fibrosis in the remnant kidney. No firm conclusions on the role of VEGF in minimal change or membranous glomerulonephritis can be drawn. VEGF may be an essential mediator of glomerular recovery in proliferative glomerulonephritis. Glomerular and tubulointerstitial repair in thrombotic microangiopathy and cyclosporin nephrotoxicity may also be VEGF-dependent. In conclusion, VEGF is required for growth and proliferation of glomerular and peritubular endothelial cells. While deleterious in some, it may contribute to recovery in other forms of renal diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149314     DOI: 10.1111/j.1523-1755.2004.00621.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  144 in total

Review 1.  Bevacizumab increases risk for severe proteinuria in cancer patients.

Authors:  Shenhong Wu; Christi Kim; Lea Baer; Xiaolei Zhu
Journal:  J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 10.121

Review 2.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

3.  C-peptide preserves the renal microvascular architecture in the streptozotocin-induced diabetic rat.

Authors:  Elizabeth R Flynn; Jonathan Lee; Zachary M Hutchens; Alejandro R Chade; Christine Maric-Bilkan
Journal:  J Diabetes Complications       Date:  2013-08-29       Impact factor: 2.852

4.  Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice.

Authors:  Athar H Siddiqui; Roxanna A Irani; Yujin Zhang; Yingbo Dai; Sean C Blackwell; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Am J Hypertens       Date:  2010-12-23       Impact factor: 2.689

5.  The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kosha Ruparel; Nancy K Sweitzer; James C Fang; Wayne C Levy; Douglas B Sawyer; Thomas P Cappola
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

Review 6.  Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.

Authors:  Alejandro R Chade
Journal:  Hypertension       Date:  2017-02-13       Impact factor: 10.190

Review 7.  Adverse effects of anticancer agents that target the VEGF pathway.

Authors:  Helen X Chen; Jessica N Cleck
Journal:  Nat Rev Clin Oncol       Date:  2009-07-07       Impact factor: 66.675

8.  Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury.

Authors:  Florian Tögel; Arthur Cohen; Ping Zhang; Ying Yang; Zhuma Hu; Christof Westenfelder
Journal:  Stem Cells Dev       Date:  2009-04       Impact factor: 3.272

9.  Early-onset Preeclampsia in Lupus Pregnancy.

Authors:  Julia F Simard; Elizabeth V Arkema; Cathina Nguyen; Elisabet Svenungsson; Anna-Karin Wikström; Kristin Palmsten; Jane E Salmon
Journal:  Paediatr Perinat Epidemiol       Date:  2016-12-12       Impact factor: 3.980

10.  Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease.

Authors:  Samy Hakroush; Marcus J Moeller; Franziska Theilig; Brigitte Kaissling; Tjeerd P Sijmonsma; Manfred Jugold; Ann L Akeson; Milena Traykova-Brauch; Hiltraud Hosser; Brunhilde Hähnel; Hermann-Josef Gröne; Robert Koesters; Wilhelm Kriz
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.